Skip to product information
1 of 3

IL-28A/IFN-λ2 Protein, Human

IL-28A/IFN-λ2 Protein, Human

Catalog Number: UA040337 Brand: UA BIOSCIENCE
Price:
Regular price $164 USD
Regular price Sale price $164 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Human
Synonyms Interferon lambda-2; IFN-lambda-2; Cytokine Zcyto20; Interleukin-28A (IL-28A);
Accession Q8IZJ0
Amino Acid Sequence

Val26-Val200, with C-terminal 8*His

Expression System HEK293
Molecular Weight

24 kDa (Reducing)

Purity >95% by SDS-PAGE and HPLC.
Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag His Tag
Physical Appearance Lyophilized Powder
Storage Buffer

PBS, pH 7.4

Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

Stability & Storage

· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.

· 3 months, -20 to -80℃ under sterile conditions after reconstitution.

· 1 week, 2 to 8℃ under sterile conditions after reconstitution.

· Please avoid repeated freeze-thaw cycles.

Reference

J Virol. 2010 Jun;84(11):5670-7.  Epub 2010 Mar 24.

Background

Interleukin-28A (IL-28A), also known as interferon lambda-2 (IFN-λ2), is a member of the type III interferon family. It is produced in response to viral infections and plays a critical role in the innate immune response. IL-28A exhibits antiviral activity by inducing the expression of interferon-stimulated genes (ISGs) and activating immune cells to inhibit viral replication and spread. IL-28A is primarily expressed by immune cells, such as dendritic cells and macrophages, and acts through the IFN-λ receptor complex to exert its antiviral effects. Due to its role in antiviral defense and immune regulation, IL-28A has garnered significant interest as a potential therapeutic target for viral infections, including hepatitis C and respiratory viruses.

Picture

Bioactivity

Measured in antiviral assays using HepG2 cells infected with vesicular stomatitis virus. The ED50 for this effect is 15-32 ng/ml.

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).

RP-HPLC

>95% as determined by RP-HPLC.